Effects of tibolone and hormone therapy (estradiol and medroxyprogesterone acetate) on the late toxic effects of radiotherapy in cervical cancer survivors: a prospective, double-blind, randomized, placebo-controlled trial

Purpose: The primary objective of this study was to investigate the efficacy of tibolone and estrogen therapies to prevent the late toxic effects of radiotherapy in the vagina in cervical cancer survivors who received radiotherapy. A secondary objective included how these therapies affected sexual life. Material and Methods: In the placebo arm, the patients received a placebo. In the tibolone arm, the patients received tibolone at a dosage of 2.5 mg daily. In the estrogen arm, patients received 0.625 mg estradiol (E2) and five mg medroxyprogesterone acetate (MPA) daily. The patients were assessed with the LENT-SOMA (Late Effects Normal Tissues-Subjective Objective Management and Analytic) scoring system, vaginal impression, female sexual function index (FSFI), and routine gynecological examination. Results: The LENTSOMA total score was significantly higher in the baseline measurement in all arms of the study (p < 0.001). The vaginal length significantly increased in the tibolone arm (7.17 ± 0.98 vs. 7.69 ± 0.91; p < 0.001) and E2/MPA arm (7.29 ± 1.37 vs. 7.80 ± 1.29; p = 0.005). The changes in FSFI total score significantly improved in the tibolone arm (16.06 ± 6.92 vs. 22.19 ± 6.14 vs. 26.02 ± 12.35; p = 0.042). Conclusions: The evidence suggested that short-term tibolone or E2/MPA use appeared to reduce the late toxic effects of radiotherapy and increase the vaginal measurements, while tibolone improved sexual function especially, in cervical cancer survivors.

Cervical cancer; Female sexual function; Estrogen; LENT-SOMA; Tibolone.

[1] Burger C.W., van Leeuwen F.E., Scheele F., Kenemans P.: “Hormone replacement therapy in women treated for gynaecological malignancy”. Maturitas, 1999, 32, 69.

[2] Hinds L., Price J.: “Menopause, hormone replacement and gynaecological cancers”. Menopause. Int., 2010, 16, 89.

[3] Brand A.H., Bull C.A., Cakir B.: “Vaginal stenosis in patients treated with radiotherapy for carcinoma of the cervix”. Int. J. Gynecol. Cancer, 2006, 16, 288.

[4] Benshushan A., Rojansky N., Chaviv M., Arbel-Alon S., Benmeir A., Imbar T., et al.: “Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy”. Climacteric, 2009, 12, 404.

[5] Brunner R.L., Gass M., Aragaki A., Hays J., Granek I., Woods N., et al.: “Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial”. Arch. Intern. Med., 2005, 165, 1976.

[6] Hlatky M.A., Boothroyd D., Vittinghoff E., Sharp P., Whooley M.A., Heart and Estrogen/Progestin Replacement Study (HERS) Research Group.: “Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial”. JAMA, 2002, 287, 591.

[7] Parker W.H., Broder M.S., Chang E., Feskanich D., Farquhar C., Liu Z., et al.: “Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study”. Obstet. Gynecol., 2009, 113, 1027.

[8] Lee K.B., Lee J.M., Lee J.K., Cho C.H.: “Endometrial cancer patients and tibolone: a matched case-control study”. Maturitas, 2006, 55, 264.

[9] Denekamp J., Bartelink H., Rubin P.: “Correction for the use of the SOMA LENT tables”. Int. J. Radiat. Oncol. Biol. Phys., 1996, 35, 417.

[10] Pavy J.J., Denekamp J., Letschert J., Littbrand B., Mornex F., Bernier J., et al.: “EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale”. Radiother. Oncol., 1995, 35, 11.

[11] Rosen R., Brown C., Heiman J., Leiblum S., Meston C., Shabsigh R., et al.: “The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function”. J. Sex. Marital. Ther., 2000, 26, 191.

[12] Oksuz E., Malhan S.: “Kadin Cinsel Fonksiyon Indeksi: Turkce uyarlamasinin gecerlilik ve guvenilirlik analizi [Reliability and validity of the Female Sexual Function Index in a Turkish population]”. Syndrome, 2005, 17, 54.

[13] Pecorelli S., Zigliani L., Odicino F.: “Revised FIGO staging for carcinoma of the cervix”. Int. J. Gynaecol. Obstet., 2009, 105, 107.

[14] Ploch E.: “Hormonal replacement therapy in patients after cervical cancer treatment”. Gynecol. Oncol., 1987, 26, 169.

[15] Greimel E.R., Winter R., Kapp K.S., Haas J.: “Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study”. Psychooncology, 2009, 18, 476.

[16] Bjelic-Radisic V., Jensen P.T., Vlasic K.K., Waldenstrom A.C., Singer S., Chie W., et al.: “Quality of life characteristics inpatients with cervical cancer”. Eur. J. Cancer, 2012, 48, 3009.

[17] Le Borgne G., Mercier M., Woronoff A.S., Guizard A.V., Abeilard E., Caravati-Jouvenceaux A., et al.: “Quality of life in long-term cervical cancer survivors: a population-based study”. Gynecol. Oncol., 2013, 129, 222.

[18] Ziaei S., Moghasemi M., Faghihzadeh S.: “Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women”. Climacteric, 2010, 13, 147.

[19] Polisseni A.F., Andrade A.T., Ribeiro L.C., Castro I.Q., Brandao M., Polisseni F., et al.: “Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study”. Maturitas, 2013, 74, 172.